Immunovant Posts 34% R&D Jump in Q1
Immunovant (NASDAQ:IMVT), a clinical-stage biotechnology company focused on therapies for autoimmune conditions, reported results for the quarter ended June 30, 2025, on August 11, 2025. Net loss per common share (GAAP) was $0.71 in Q1 FY2026. Research and development expenses rose sharply as the company continued pushing its lead anti-neonatal Fc receptor (FcRn) antibody, IMVT-1402, through six separate clinical trials. No revenue was reported as Immunovant remains pre-commercial. Overall, the period demonstrated increased spending to advance its pipeline.
Source: Analyst estimates for the quarter provided by FactSet.
Immunovant is advancing therapies that target autoimmune diseases, with its primary asset being IMVT-1402, an antibody designed to inhibit the neonatal Fc receptor. This approach aims to reduce the level of Immunoglobulin G (IgG), a type of antibody that can play a role in immune system attacks on the body’s own tissues. By lowering IgG, Immunovant targets underlying causes of conditions such as Graves’ disease and myasthenia gravis.
Source Fool.com
